Winning is getting easier: management describes the effort needed to land each new piece of business visibly falling, wi
The model's full reasoning — Q3 2016 call → NOWe need to determine if management conveys that winning business has become easier than it used to be, with real recent proof and still in effect. The transcript is about Fate Therapeutics, a biotech company. The "business" here is likely clinical development, regulatory approvals, partnerships, etc. But the question is about winning business: landing customers, orders, contracts, expansions. In biotech, that could be partnerships, collaborations, or perhaps regulatory approvals that enable business. However, the transcript focuses on clinical trials, IND filings, and product development. There is mention of a partnership with Memorial Sloan-Kettering, and a collaboration with Juno. But does management say that winning these deals has become easier? Let's scan. Management talks about progress: "substantial progress", "intensified our clinical commitment", "FDA granted fast-track and Orphan Drug designations", "EMA granted Orphan Medicinal Product designation", "recently amended our clinical trial protocol to blind both investigators and subjects... which we believe substantially enhances the PROTECT Study's potential to support accelerated registration". They also mention "successful pre-IND meeting with the FDA" for FATE-NK100, and "positive pre-IND meeting" for ToleraCyte. They talk about forming a partnership with Memorial Sloan-Kettering. But do they say that winning these partnerships or regulatory approvals has become easier than before? They don't explicitly compare to past difficulty. They describe progress and achievements, but not a contrast that winning business is now easier. They mention "we have the opportunity to be the first group to ever advance an engineered iPSC derived cancer immunotherapy into clinical development" - that's about being first, not easier. They also mention "we are actively discussing the product candidates novel mechanism of action with key opinion leaders, clinical investigators and potential partners" - that's ongoing discussions, not necessarily easier. The question asks specifically about "winning business" - landing new customers, orders, contracts, expansions. In this context, perhaps partnerships or collaborations. But management does not say that it used to be harder and now it's easier. They don't mention any comparison to their own past.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| ACGL | Arch Capital Group Ltd. | Q4 2023 | 2024-02-15 | B+ |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| ACCO | ACCO Brands Corporation | Q1 2016 | 2016-04-27 | B+ |
ACCO · Q1 2016 → YESThe question is: Does management convey that IT HAS RECENTLY BECOME EASIER FOR THE COMPANY TO WIN BUSINESS THAN IT USED TO BE, based on real recent wins, and still in effect. YES The transcript shows management conveying that winning business has become easier than in the company's recent past. Boris Elisman states that customers have seen the value of the company's strong brands during the past couple of seasons, resulting in broader and deeper penetration in mass retailers and continued share gains.
NICE · Q4 2023 → YESThe question is: Does management convey that IT HAS RECENTLY BECOME EASIER FOR THE COMPANY TO WIN BUSINESS THAN IT USED TO BE, grounded in real business won recently, and still in effect.
VRNS · Q2 2016 → YESThe question is whether management conveys that it has recently become easier for the company to win business than it used to be, grounded in real recent wins, and still in effect.